Could Cetuximab Maintenance Play a Role in RAS Wild-Type Metastatic CRC?

(MedPage Today) -- Maintenance therapy with cetuximab (Erbitux) after FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus cetuximab induction therapy led to better outcomes for patients with RAS wild-type metastatic colorectal cancer (CRC...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news